(MedPage Today) — BERLIN — A Chinese trial that screened advanced urothelial cancer patients for HER2-expression demonstrated a large survival benefit with a novel chemotherapy-free combination in the first-line setting, though it’s unclear…
Source link : https://www.medpagetoday.com/meetingcoverage/esmo/118060
Author :
Publish date : 2025-10-21 15:21:00
Copyright for syndicated content belongs to the linked Source.
